---
title: "GlaxoSmithKline (Belgium): research papers"
description: "From 2017 to 2026 (so far), authors at GlaxoSmithKline (Belgium) took part in 30 papers in the tracked journals, most of them in health economics and policy (25) and statistics (5). 2 of them were published in 2025, against 2 in 2017."
url: https://scholar4ai.com/companies/glaxosmithkline-belgium
markdown_url: https://scholar4ai.com/companies/glaxosmithkline-belgium.md
license: CC BY-NC 4.0 (https://creativecommons.org/licenses/by-nc/4.0/)
share_text: "From 2017 to 2026 (so far), authors at GlaxoSmithKline (Belgium) took part in 30 papers in the tracked journals, most of them in health economics and policy (25) and statistics (5). 2 of them were published in 2025… (as of 2026-11-05)"
data_url: https://scholar4ai.com/data/rankings.json
updated: 2026-11-05T06:02:37+09:00
window: 2026-10-07 to 2026-11-05
source: OpenAlex (CC0)
---

# GlaxoSmithKline (Belgium)

[Browse company research profiles](https://scholar4ai.com/companies/directory/page/2.md)

Papers in the tracked journals with an author at GlaxoSmithKline (Belgium): per year and category, where they are published, the institutions its researchers write with, and its most-cited papers. A paper counts as corporate when at least one of its authors is affiliated with an institution that OpenAlex classifies as a company; it counts once for each company among its authors' affiliations. Universities are the institutions OpenAlex classifies as education.

Back to the ranking: https://scholar4ai.com/rankings/companies.md

## Key findings

- From 2017 to 2026 (so far), authors at GlaxoSmithKline (Belgium) took part in 30 papers in the tracked journals, most of them in health economics and policy (25) and statistics (5).
- 2 of them were published in 2025, against 2 in 2017.
- Since 2023, the institutions with the most of these papers were RTI Health Solutions (6), GlaxoSmithKline (United States) (5) and GlaxoSmithKline (United Kingdom) (4).
- The journals publishing most of them were PharmacoEconomics - Open (7), PharmacoEconomics (3) and The European Journal of Health Economics (3).
- The most-cited of them is “Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults” (Applied Health Economics and Health Policy, 2019), with 41 citations.
- Since 2023, papers in the tracked journals cited 7 of its papers 11 times; 45% of those links came from papers with a university author and 73% from its own papers.
- Its own papers since 2023 cite archived papers 19 times, 47% of them papers with a company author.
- Across everything OpenAlex indexes, GlaxoSmithKline (Belgium) has 3,490 works with 494,967 citations (h-index 269).
- The tracked journals hold 25 of its 1,611 works in OpenAlex from 2017 to 2025 (1.6%).
- Its main research topics in OpenAlex are Bacterial Infections and Vaccines (968), Pneumonia and Respiratory Infections (498) and Health Systems, Economic Evaluations, Quality of Life (452).
- OpenAlex lists it under GlaxoSmithKline (United Kingdom).

## Papers per year

*Papers per publication year and category*

| Category | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (so far) |
|---|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|
| [Health Economics and Policy](https://scholar4ai.com/categories/health-economics-and-policy.md) | 2 | 0 | 5 | 0 | 1 | 2 | 2 | 6 | 2 | 5 |
| [Statistics](https://scholar4ai.com/categories/statistics.md) | 0 | 0 | 1 | 1 | 3 | 0 | 0 | 0 | 0 | 0 |
| All categories | 2 | 0 | 6 | 1 | 4 | 2 | 2 | 6 | 2 | 5 |

## Where the papers come from

*Journals with the most papers, since 2023*

| # | Journal | Papers |
|---:|---|---:|
| 1 | [PharmacoEconomics - Open](https://scholar4ai.com/journals/pharmacoeconomics-open.md) | 7 |
| 2 | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 3 |
| 3 | [The European Journal of Health Economics](https://scholar4ai.com/journals/the-european-journal-of-health-economics.md) | 3 |
| 4 | [Human Resources for Health](https://scholar4ai.com/journals/human-resources-for-health.md) | 1 |
| 5 | [Health Policy and Technology](https://scholar4ai.com/journals/health-policy-and-technology.md) | 1 |

*Institutions with the most papers, since 2023*

| # | Institution | Papers |
|---:|---|---:|
| 1 | RTI Health Solutions | 6 |
| 2 | GlaxoSmithKline (United States) | 5 |
| 3 | [GlaxoSmithKline (United Kingdom)](https://scholar4ai.com/companies/glaxosmithkline-united-kingdom.md) | 4 |
| 4 | GlaxoSmithKline Research & Development Limited (United Kingdom) | 3 |
| 5 | GlaxoSmithKline (Canada) | 2 |
| 6 | [London School of Hygiene & Tropical Medicine](https://scholar4ai.com/institutions/london-school-of-hygiene-tropical-medicine.md) | 2 |
| 7 | Padjadjaran University | 2 |
| 8 | Universitas Airlangga | 2 |
| 9 | University Medical Center Groningen | 2 |

*Countries with the most papers, since 2023*

| # | Country | Papers |
|---:|---|---:|
| 1 | Belgium | 15 |
| 2 | United States | 8 |
| 3 | United Kingdom | 5 |
| 4 | Canada | 3 |
| 5 | Indonesia | 2 |
| 6 | Netherlands | 2 |
| 7 | Austria | 1 |
| 8 | Germany | 1 |
| 9 | France | 1 |
| 10 | Greece | 1 |

*Keywords with the most papers, since 2023*

| # | Keyword | Papers |
|---:|---|---:|
| 1 | [quality-adjusted life years](https://scholar4ai.com/keywords/quality-adjusted-life-years.md) | 8 |
| 2 | [cost-effectiveness](https://scholar4ai.com/keywords/cost-effectiveness.md) | 7 |
| 3 | invasive meningococcal disease | 6 |
| 4 | public health impact | 5 |
| 5 | recombinant zoster vaccine | 5 |
| 6 | herpes zoster | 4 |
| 7 | [older adults](https://scholar4ai.com/keywords/older-adults.md) | 4 |
| 8 | vaccination coverage | 4 |
| 9 | [health care costs](https://scholar4ai.com/keywords/health-care-costs.md) | 3 |
| 10 | postherpetic neuralgia | 3 |

## Most-cited papers

*Most-cited papers since 2017*

| # | Citations | Per month | Title | Journal | Published | Authors |
|---:|---:|---:|---|---|---|---|
| 1 | 41 | 0.5 | [Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults](https://doi.org/10.1007/s40258-019-00491-6) | [Applied Health Economics and Health Policy](https://scholar4ai.com/journals/applied-health-economics-and-health-policy.md) | 2019-06-28 | Ashleigh A. McGirr, Desirée Van Oorschot, Robyn Widenmaier et al. |
| 2 | 34 | 0.8 | [Artificial intelligence and pharmacovigilance: What is happening, what could happen and what should happen?](https://doi.org/10.1016/j.hlpt.2023.100743) | [Health Policy and Technology](https://scholar4ai.com/journals/health-policy-and-technology.md) | 2023-04-15 | Andrew Bate, Jens‐Ulrich Stegmann |
| 3 | 20 | 0.4 | [Direct Medical Costs of Four Vaccine-Preventable Infectious Diseases in Older Adults in Spain](https://doi.org/10.1007/s41669-022-00329-3) | [PharmacoEconomics - Open](https://scholar4ai.com/journals/pharmacoeconomics-open.md) | 2022-03-07 | Ángel Gil de Miguel, José María Eirós Bouza, L.I. Martínez-Alcorta et al. |
| 4 | 14 | 0.2 | [Constrained Optimization for the Selection of Influenza Vaccines to Maximize the Population Benefit: A Demonstration Project](https://doi.org/10.1007/s40258-019-00534-y) | [Applied Health Economics and Health Policy](https://scholar4ai.com/journals/applied-health-economics-and-health-policy.md) | 2019-11-22 | Baudouin A. Standaert, Ilse Van Vlaenderen, Laure-Anne Van Bellinghen et al. |
| 5 | 14 | 0.2 | [Addressing vaccine supply challenges in Europe: Expert industry perspective and recommendations](https://doi.org/10.1016/j.healthpol.2021.11.006) | [Health Policy](https://scholar4ai.com/journals/health-policy.md) | 2021-11-28 | Muriel Pasté, Michel Stoffel, Corinne Bardone et al. |
| 6 | 11 | 0.1 | [Improving the Hospital Quality of Care during Winter Periods by Optimizing Budget Allocation Between Rotavirus Vaccination and Bed Expansion](https://doi.org/10.1007/s40258-017-0362-6) | [Applied Health Economics and Health Policy](https://scholar4ai.com/journals/applied-health-economics-and-health-policy.md) | 2017-11-20 | Thibaut Dort, Nadia Schecroun, Baudouin A. Standaert |
| 7 | 9 | 0.5 | [Costs and Complications of Respiratory Syncytial Virus and Acute Respiratory Infections in the Adult Population: Analysis of a German Claims Database](https://doi.org/10.1007/s41669-025-00565-3) | [PharmacoEconomics - Open](https://scholar4ai.com/journals/pharmacoeconomics-open.md) | 2025-03-19 | Pavo Marijic, Roman Kliemt, M. Krammer et al. |
| 8 | 8 | 0.1 | [Optimising the introduction of multiple childhood vaccines in Japan: A model proposing the introduction sequence achieving the highest health gains](https://doi.org/10.1016/j.healthpol.2017.08.010) | [Health Policy](https://scholar4ai.com/journals/health-policy.md) | 2017-09-22 | Baudouin A. Standaert, Nadia Schecroun, Olivier Ethgen et al. |
| 9 | 8 | 0.2 | [Cost-Effectiveness of Recombinant Zoster Vaccine for the Prevention of Herpes Zoster in Hematopoietic Stem Cell Transplant Recipients and Other Immunocompromised Adults in the United States](https://doi.org/10.1007/s41669-023-00438-7) | [PharmacoEconomics - Open](https://scholar4ai.com/journals/pharmacoeconomics-open.md) | 2023-11-01 | Ahmed Salem, Elizabeth M. La, Desmond Curran et al. |
| 10 | 8 | 0.3 | [Public Health Impact of Introducing a Pentavalent Vaccine Against Invasive Meningococcal Disease in the United States](https://doi.org/10.1007/s40273-024-01439-y) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 2024-11-25 | Hiral Anil Shah, Ginita Jutlla, Oscar Herrera-Restrepo et al. |

## Who cites its research

*Institutions whose papers cite it most, since 2023*

| # | Institution | Kind | Country | Links |
|---:|---|---|---|---:|
| 1 | GlaxoSmithKline (United States) | Company | United States | 5 |
| 2 | RTI Health Solutions | Nonprofit | United States | 4 |
| 3 | [GlaxoSmithKline (United Kingdom)](https://scholar4ai.com/companies/glaxosmithkline-united-kingdom.md) | Company | United Kingdom | 3 |
| 4 | GlaxoSmithKline Research & Development Limited (United Kingdom) | Company | United Kingdom | 3 |
| 5 | University Medical Center Groningen | Healthcare | Netherlands | 2 |
| 6 | [University of Groningen](https://scholar4ai.com/institutions/university-of-groningen.md) | University | Netherlands | 2 |
| 7 | Universitas Airlangga | University | Indonesia | 2 |
| 8 | Comprehensive Health Research Centre | University | Portugal | 2 |
| 9 | Universidade Nova de Lisboa | University | Portugal | 2 |

## What its papers cite

*Institutions its papers cite most, since 2023*

| # | Institution | Kind | Country | Links |
|---:|---|---|---|---:|
| 1 | RTI Health Solutions | Nonprofit | United States | 4 |
| 2 | [GlaxoSmithKline (United Kingdom)](https://scholar4ai.com/companies/glaxosmithkline-united-kingdom.md) | Company | United Kingdom | 3 |
| 3 | GlaxoSmithKline (United States) | Company | United States | 3 |
| 4 | GlaxoSmithKline (Canada) | Company | Canada | 3 |
| 5 | GlaxoSmithKline Research & Development Limited (United Kingdom) | Company | United Kingdom | 3 |
| 6 | École Supérieure des Sciences Économiques et Commerciales | Other | France | 2 |
| 7 | GlaxoSmithKline (France) | Company | France | 2 |
| 8 | [Health Economics and Outcomes Research (United Kingdom)](https://scholar4ai.com/companies/health-economics-and-outcomes-research-united-kingdom.md) | Company | United Kingdom | 2 |
| 9 | [Concordia University](https://scholar4ai.com/institutions/concordia-university.md) | University | Canada | 2 |

More: https://scholar4ai.com/corporate-citations.md · https://scholar4ai.com/industry-university.md

## In OpenAlex

*GlaxoSmithKline (Belgium) in OpenAlex*

| Item | Value |
|---|---|
| Type | Company |
| Location | Wavre, Wallonia, Belgium |
| Also known as | GSK |
| Part of | [GlaxoSmithKline (United Kingdom)](https://scholar4ai.com/companies/glaxosmithkline-united-kingdom.md) |
| Works in OpenAlex | 3,490 |
| Citations | 494,967 |
| h-index | 269 |
| i10-index | 5,802 |
| 2-year mean citedness | 9.46 |
| Website | [be.gsk.com](http://be.gsk.com/) |
| ROR | [ror.org/00n3pea85](https://ror.org/00n3pea85) |
| OpenAlex | [openalex.org/I4210095529](https://openalex.org/I4210095529) |

*Works and citations per year in OpenAlex, and its papers in the tracked journals*

| Year | Works in OpenAlex | Citations received | In the tracked journals | Share |
|---|---:|---:|---:|---:|
| 2026 (so far) | 123 | 9,983 | 5 | 4.1% |
| 2025 | 164 | 13,247 | 2 | 1.2% |
| 2024 | 204 | 13,404 | 6 | 2.9% |
| 2023 | 179 | 13,115 | 2 | 1.1% |
| 2022 | 172 | 12,376 | 2 | 1.2% |
| 2021 | 179 | 13,709 | 4 | 2.2% |
| 2020 | 187 | 11,384 | 1 | 0.5% |
| 2019 | 193 | 9,981 | 6 | 3.1% |
| 2018 | 172 | 8,917 | 0 | 0.0% |
| 2017 | 161 | 9,248 | 2 | 1.2% |

*Main research topics (OpenAlex, all works)*

| # | Topic | Field | Works |
|---:|---|---|---:|
| 1 | Bacterial Infections and Vaccines | Immunology and Microbiology | 968 |
| 2 | Pneumonia and Respiratory Infections | Medicine | 498 |
| 3 | Health Systems, Economic Evaluations, Quality of Life | Economics, Econometrics and Finance | 452 |
| 4 | Vaccine Coverage and Hesitancy | Social Sciences | 439 |
| 5 | Immunotherapy and Immune Responses | Immunology and Microbiology | 397 |

From OpenAlex's own record of the institution (CC0), read again monthly. Works and citations count everything OpenAlex indexes, not only the tracked journals; topics are OpenAlex's classification of those works.

## Cite this page

Scholar4AI. (2026). GlaxoSmithKline (Belgium). Journal and Conference Research Rankings. Retrieved November 5, 2026, from https://scholar4ai.com/companies/glaxosmithkline-belgium

```bibtex
@misc{scholar4ai-companies-glaxosmithkline-belgium,
  author = {{Scholar4AI}},
  title = {GlaxoSmithKline (Belgium)},
  year = {2026},
  howpublished = {\url{https://scholar4ai.com/companies/glaxosmithkline-belgium}},
  urldate = {2026-11-05},
  note = {Journal and Conference Research Rankings; data from OpenAlex (CC0); licensed CC BY-NC 4.0}
}
```

License: CC BY-NC 4.0 (https://creativecommons.org/licenses/by-nc/4.0/).